Seer Inc (SEER)

NASD · Healthcare · Biotechnology · USA

Seer Inc is a micro cap company (market value under $300 million) in the Biotechnology industry.

Seer Inc offers the Proteograph Product Suite, a proteomics platform enabling researchers to conduct comprehensive, unbiased protein analysis at scale. The offering combines consumable assays, automation equipment, and analytical software to support protein discovery, disease investigation, and biomarker development. The company serves customers in research, drug development, sample repositories, and clinical study settings worldwide.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Seer Inc stock.

Our verdict on SEER

Undervalued: intrinsic value $2.95 per share, market price $1.46, margin of safety 50.5% (as of 2026-11-17).

Its liquidation floor, current assets minus every liability, values the shares at $2.95; the price of $1.46 is 51% below that value.

ETFs with the most weight in SEER

8 more funds hold it; the full list is part of the paid plan.

More on SEER

Browse

Peers in Biotechnology

All 600 Biotechnology stocks

Cheaper than SEER in Biotechnology

6 more in this industry show a wider margin of safety.

Is SEER undervalued or overvalued?

SEER is undervalued (as of the 2026-11-17 close). Its liquidation floor, current assets minus every liability, values the shares at $2.95; the price of $1.46 is 51% below that value.

What is the intrinsic value of SEER?

$2.95 per share (as of the 2026-11-17 close), against a market price of $1.46. That is a margin of safety of 50.5%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.